The PhosphoPlus® MEK1/2 (Ser217/221) Antibody Kit provides reagents and protocols for the rapid analysis of the phosphorylation status of MEK1/2 at Ser217/221.
Phospho-MEK1/2 (Ser217/221) Antibody detects endogenous levels of MEK1/2 only when phosphorylated at serines 217 and 221. It will also react with MEK1/2 singly phosphorylated at Ser217 and singly phosphorylated at Ser221. MEK1/2 (D1A5) Rabbit mAb recognizes endogenous levels of total MEK1 and MEK2 proteins.
Monoclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues around Ser217/221 of human MEK1/2 and synthetic peptide corresponding to residues surrounding Ala220 of human MEK1 protein.
MEK1 and MEK2, also called MAPK or Erk kinases, are dual-specificity protein kinases that function in a mitogen activated protein kinase cascade controlling cell growth and differentiation (1-3). Activation of MEK1 and MEK2 occurs through phosphorylation of two serine residues at positions 217 and 221, located in the activation loop of subdomain VIII, by Raf-like molecules. MEK1/2 is activated by a wide variety of growth factors and cytokines and also by membrane depolarization and calcium influx (1-4). Constitutively active forms of MEK1/2 are sufficient for the transformation of NIH/3T3 cells or the differentiation of PC-12 cells (4). MEK activates p44 and p42 MAP kinase by phosphorylating both threonine and tyrosine residues at sites located within the activation loop of kinase subdomain VIII.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. PhosphoPlus is a trademark of Cell Signaling Technology, Inc. LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories. U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
Explore pathways related to this product.